Lyra Therapeutics Analyst Ratings
Lyra Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 291.64% | BTIG | → $15 | Assumes | → Buy |
| 10/02/2023 | 213.32% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 09/12/2023 | 291.64% | B of A Securities | $13 → $15 | Maintains | Buy |
| 08/31/2023 | 213.32% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 02/07/2023 | 422.19% | BTIG | $24 → $20 | Maintains | Buy |
| 05/24/2022 | 291.64% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
| 05/26/2020 | 448.3% | B of A Securities | → $21 | Initiates Coverage On | → Buy |
| 05/26/2020 | 526.63% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/06/2023 | 291.64% | BTIG | →$15 | 假設 | →購買 |
| 10/02/2023 | 213.32% | HC Wainwright公司 | →$12 | 重申 | 購買→購買 |
| 09/12/2023 | 291.64% | B of A證券 | $13→$15 | 維護 | 買 |
| 2023年08月31日 | 213.32% | HC Wainwright公司 | →$12 | 開始承保 | →購買 |
| 02/07/2023 | 422.19% | BTIG | $24→$20 | 維護 | 買 |
| 2022年05月24日 | 291.64% | 康託·菲茨傑拉德 | →$15 | 開始承保 | →超重 |
| 05/26/2020 | 448.3% | B of A證券 | →$21 | 開始承保 | →購買 |
| 05/26/2020 | 526.63% | 傑富瑞 | →$24 | 開始承保 | →購買 |
What is the target price for Lyra Therapeutics (LYRA)?
Lyra治療公司(Lyra)的目標價格是多少？
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by BTIG on October 6, 2023. The analyst firm set a price target for $15.00 expecting LYRA to rise to within 12 months (a possible 291.64% upside). 5 analyst firms have reported ratings in the last year.
萊拉治療公司(納斯達克：萊拉)的最新目標價是由BTIG於2023年10月6日報道的。這家分析公司將目標價定為15美元，預計Lyra將在12個月內上漲至(可能上漲291.64)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Lyra Therapeutics (LYRA)?
天琴座治療公司(Lyra)的最新分析師評級是多少？
The latest analyst rating for Lyra Therapeutics (NASDAQ: LYRA) was provided by BTIG, and Lyra Therapeutics their buy rating.
萊拉治療公司(納斯達克：萊拉)的最新分析師評級是由北大西洋投資集團提供的，萊拉治療公司的最新評級為買入。
When is the next analyst rating going to be posted or updated for Lyra Therapeutics (LYRA)?
Lyra治療公司(Lyra)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyra Therapeutics was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Lyra治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Lyra治療公司的上一次評級是在2023年10月6日提交的，所以你應該預計下一次評級將在2024年10月6日左右的某個時候提供。
Is the Analyst Rating Lyra Therapeutics (LYRA) correct?
分析師對Lyra Treateutics(Lyra)的評級正確嗎？
While ratings are subjective and will change, the latest Lyra Therapeutics (LYRA) rating was a with a price target of $0.00 to $15.00. The current price Lyra Therapeutics (LYRA) is trading at is $3.83, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Lyra治療公司(Lyra)評級為A，目標價在0.00美元至15.00美元之間。Lyra治療公司(Lyra)目前的交易價格為3.83美元，在分析師的預測範圍內。